Arturo Vegas - Sigilon Therapeutics CoFounder

Insider

Arturo Vegas is CoFounder of Sigilon Therapeutics
Phone617 336 7540
Webhttps://www.sigilon.com

Sigilon Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2365) % which means that it has lost $0.2365 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7631) %, meaning that it created substantial loss on money invested by shareholders. Sigilon Therapeutics' management efficiency ratios could be used to measure how well Sigilon Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Sigilon Therapeutics currently holds 28.06 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Sigilon Therapeutics has a current ratio of 2.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Sigilon Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

CGA CPAInMed Pharmaceuticals
N/A
Ado MuhammadInMed Pharmaceuticals
N/A
LaBella MSZyVersa Therapeutics
66
Pablo MDZyVersa Therapeutics
N/A
Karen CashmereZyVersa Therapeutics
73
Colin ClancyInMed Pharmaceuticals
N/A
Arthur TaverasX4 Pharmaceuticals
61
Narayan PrabhuReviva Pharmaceuticals Holdings
53
Renato SkerljX4 Pharmaceuticals
N/A
MBA JDCardio Diagnostics Holdings
60
Meeshanthini DoganCardio Diagnostics Holdings
36
Susan DexterSonnet Biotherapeutics Holdings
70
Yenyou ZhengNovaBay Pharmaceuticals
62
Mary DiBiaseX4 Pharmaceuticals
64
McKee MDGeoVax Labs
72
Wang XuNovaBay Pharmaceuticals
36
MPA MDUnicycive Therapeutics
52
Keith MDX4 Pharmaceuticals
54
CPA CPAGeoVax Labs
62
Jeffrey WelchGeoVax Labs
N/A
Justin EsqNovaBay Pharmaceuticals
47
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people. Sigilon Therapeutics (SGTX) is traded on NASDAQ Exchange in USA and employs 62 people.

Management Performance

Sigilon Therapeutics Leadership Team

Elected by the shareholders, the Sigilon Therapeutics' board of directors comprises two types of representatives: Sigilon Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sigilon. The board's role is to monitor Sigilon Therapeutics' management team and ensure that shareholders' interests are well served. Sigilon Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sigilon Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Philip AshtonRickardt, Chief Officer
MD MBA, Ex Officer
Arturo Vegas, CoFounder
Omid Veiseh, CoFounder
Daniel Anderson, CoFounder Board
MBA MD, CEO Pres
Jos MD, CoFounder
JD Windsor, VP Relations
Josias MBA, VP, CFO

Sigilon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sigilon Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in Sigilon Stock

If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Stocks Directory
Find actively traded stocks across global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device